Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Fax: 206 902 9658

Website: www.atossatherapeutics.com

Address:

107 Spring Street, Seattle, United States

Warrens__Buffet_ Feb. 20 at 6:39 PM

$ATOS still pumping when it’s still falling 😂 down 60% post split and counting. This guy will be saying “be live in the science” when the company goes to zero. Know your bull, know your poster.

0 · Reply

Kittyc803 Feb. 20 at 6:37 PM

$ATOS And so it goes ……… Have a great weekend people

0 · Reply

MoMoney80 Feb. 20 at 6:36 PM

$ATOS this the bottom? Good time to buy? I know this has been diving since reverse split but seems to be a promising investment. Is now the time asking for any longs thoughts..thanks

1 · Reply

DaddyFarquhar Feb. 20 at 6:19 PM

$ATOS Please not again !

0 · Reply

Uberdawg Feb. 20 at 6:12 PM

$ATOS MM’s just playing tag

0 · Reply

dcajic2 Feb. 20 at 5:37 PM

$ATOS Management continues to get paid money despite doing everything wrong with regards to shareholders. They could Have for help many years ago to advance endoxifen. But they still get big money for holding back research. They haven’t even fully enrolled phase 2 patients for bigger study. Ignore all Bullish people because they literally are lying.

0 · Reply

dcajic2 Feb. 20 at 5:34 PM

$ATOS Management is not for the shareholders. If they were they would Have continued on with th research and voluntary delisted from the Nasdaq. This would have saved present shareholders many dollars since I the OTC they would Not have been shorted into nothingness.

0 · Reply

Warrens__Buffet_ Feb. 20 at 4:34 PM

$ATOS andddd like I called. Big dump falling back down

1 · Reply

Warrens__Buffet_ Feb. 20 at 4:04 PM

$ATOS will fall back down soon and the pumping bull who came out of the woodwork for their little 2% recovery on the 60% dip post split will disappear

0 · Reply

Warrens__Buffet_ Feb. 20 at 4:00 PM

$ATOS

0 · Reply

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Feb 5, 2026, 8:30 AM EST - 15 days ago

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Jan 21, 2026, 9:05 AM EST - 4 weeks ago

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

Jan 16, 2026, 4:40 PM EST - 4 weeks ago

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

Jan 6, 2026, 8:15 AM EST - 6 weeks ago

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Dec 17, 2025, 8:15 AM EST - 2 months ago

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Dec 15, 2025, 8:00 AM EST - 2 months ago

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Dec 11, 2025, 8:00 AM EST - 2 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Dec 9, 2025, 8:00 AM EST - 2 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Dec 4, 2025, 8:00 AM EST - 2 months ago

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Dec 2, 2025, 8:00 AM EST - 2 months ago

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Nov 17, 2025, 9:07 AM EST - 3 months ago

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Nov 12, 2025, 8:15 AM EST - 3 months ago

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 3 months ago

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Oct 21, 2025, 8:00 AM EDT - 4 months ago

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 4 months ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 4 months ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 4 months ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 5 months ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 8:30 AM EDT - 5 months ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 6 months ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 6 months ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 6 months ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 29, 2025, 7:45 AM EDT - 7 months ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 2, 2025, 8:45 AM EDT - 9 months ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 9 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 10 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 10 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 8:45 AM EDT - 10 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 10 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 10 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 11 months ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 25, 2025, 10:05 AM EDT - 11 months ago

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 1 year ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Feb 5, 2025, 8:00 AM EST - 1 year ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Jan 30, 2025, 8:17 AM EST - 1 year ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 23, 2025, 8:15 AM EST - 1 year ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Dec 12, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 10, 2024, 9:05 AM EST - 1 year ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 9, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 20, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 12, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Nov 4, 2024, 6:30 AM EST - 1 year ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Warrens__Buffet_ Feb. 20 at 6:39 PM

0 · Reply

Kittyc803 Feb. 20 at 6:37 PM

$ATOS And so it goes ……… Have a great weekend people

0 · Reply

MoMoney80 Feb. 20 at 6:36 PM

$ATOS this the bottom? Good time to buy? I know this has been diving since reverse split but seems to be a promising investment. Is now the time asking for any longs thoughts..thanks

1 · Reply

DaddyFarquhar Feb. 20 at 6:19 PM

$ATOS Please not again !

0 · Reply

Uberdawg Feb. 20 at 6:12 PM

$ATOS MM’s just playing tag

0 · Reply

dcajic2 Feb. 20 at 5:37 PM

0 · Reply

dcajic2 Feb. 20 at 5:34 PM

0 · Reply

Warrens__Buffet_ Feb. 20 at 4:34 PM

$ATOS andddd like I called. Big dump falling back down

1 · Reply

Warrens__Buffet_ Feb. 20 at 4:04 PM

$ATOS will fall back down soon and the pumping bull who came out of the woodwork for their little 2% recovery on the 60% dip post split will disappear

0 · Reply

Warrens__Buffet_ Feb. 20 at 4:00 PM

$ATOS

0 · Reply

walker7782 Feb. 20 at 3:59 PM

$ATOS Liquidity vacuum

1 · Reply

Bunster Feb. 20 at 3:32 PM

$ATOS to prime this looks like the alamo with some of u delusional bulls are crockett and travers and bowie while QUAY is SANTA ANA

0 · Reply

Bunster Feb. 20 at 3:21 PM

$ATOS no volume with many of bios on my wl.if the volume went to 100k today would pps be 5 or 4?????????????????

1 · Reply

Bunster Feb. 20 at 3:18 PM

$ATOS the rightest poster in our forum by far dcaj is shorting allegedly down here. if true thats a gamble imo.but what do i know. i would not have shorted at 60c or 80c and now its down to 30c

0 · Reply

Bunster Feb. 20 at 3:14 PM

$ATOS lets take a look at some of the prior bulls who are gone or long gone.WHAT DOES THAT TELL U ? These are posters u bulls loved and liked their nonsense and pumping all day long. pompom boy dharl 24 7 kino gungadin waterboy owl of the night rocketboy allthough he came back in after a short stay away scores of others

0 · Reply

dcajic2 Feb. 20 at 3:02 PM

$ATOS shorting more. Pure and utter bullish nonsense. Merely a phase 2 company that has been researching for the better part of a decade. They still haven’t fully enrolled women in the bigger phase 2 study that they need in order to get fda approval.

0 · Reply

Jdawz Feb. 20 at 2:14 PM

$ATOS Surprise us Doctor!

1 · Reply

Kittyc803 Feb. 20 at 12:43 PM

$ATOS

1 · Reply

DCalcote Feb. 20 at 12:28 PM

$ATOS

0 · Reply

NOYES Feb. 20 at 1:14 AM

$ATOS Let's see

1 · Reply

Lion0fWallSt Feb. 20 at 1:03 AM

$KLAR $SLS $CADL $ATOS $CAPR It could work out great for Mr Calvin @CJ27969, he lost his live savings on ATOS

3 · Reply

Uberdawg Feb. 20 at 12:34 AM

$ATOS Tomorrow should be interesting for BIOs. I’m waking up early. This is a moment to observe and learn. This is a complex change for companies. Can of worms around liability and all new protocols need to be designed. Wishing everyone much success and happiness

1 · Reply

Market Cap	37.39M
Revenue (ttm)	0.00
Net Income (ttm)	-25.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	18,483
Avg Vol	158,617
Day's Range	N/A - N/A
Shares Out	8.62M
Stochastic %K	33%
Beta	1.36
Analysts	Strong Sell
Price Target	$25.00